Relmada Therapeutics (RLMD) Profit After Tax (2012 - 2026)

Relmada Therapeutics (RLMD) has reported Profit After Tax for 15 consecutive years, with -$19.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax fell 8.5% year-over-year to -$19.1 million; the TTM figure through Mar 2026 stood at -$58.9 million (up 22.23% YoY), while the FY2025 annual figure was -$57.4 million, up 28.25% from the prior year.
• Profit After Tax improved to -$19.1 million in Q1 2026 per RLMD's latest filing, from -$19.9 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$9.9 million in Q2 2025 and bottomed at -$39.9 million in Q2 2022.
• Historically, Profit After Tax has averaged -$24.3 million across 5 years, with a median of -$21.8 million in 2024.
• Annual changes were most pronounced in 2022 — Profit After Tax plunged 78.91% — and 2025, when it surged 53.55%.
• Relmada Therapeutics' Profit After Tax stood at -$37.9 million in 2022, then jumped by 33.68% to -$25.2 million in 2023, then increased by 25.86% to -$18.7 million in 2024, then retreated by 6.49% to -$19.9 million in 2025, then grew by 4.11% to -$19.1 million in 2026.
• Business Quant data shows RLMD's Profit After Tax at -$19.1 million in Q1 2026, -$19.9 million in Q4 2025, and -$10.1 million in Q3 2025.